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Abstract
Objective: To assess the long-term response to add-on quetiapine therapy in patients with bipolar
I disorder who were not adequately responding to standard medications.
Methods: Outpatients with bipolar I disorder (DSM-IV-TR) responding inadequately to standard
treatment were observed before and after the addition of quetiapine. Symptom severity was
evaluated using the Clinical Global Impressions scale for Bipolar Disorder (CGI-BP) each month.
Relapses included hospitalization, treatment in a day hospital or clinic, scores ≥ 1 point higher than
previous CGI-BP scores and/or upward titration of quetiapine or other medications.
Results: Sixty-one patients (age range of 18–68 years) were observed prospectively for an average
of 7.5 months (range 3–18 months) prior to addition of quetiapine and subsequently followed for
an average of 15.7 months (range 6–42 months). The final mean quetiapine dose was 537.1 ± 91.7
mg/d. Prior to quetiapine addition, an annual relapse rate of 2.09 episodes was recorded, relating
to 0.94 depressive and 1.15 manic or mixed episodes. Following quetiapine addition, annual relapse
rates were reduced to 0.61 episodes, representing 0.14 depressive and 0.46 manic or mixed
episodes. Compared with the period of add-on quetiapine treatment, the relative risk of relapse
prior to quetiapine therapy was 3.4 for all episodes (χ2 = 24.8, P < 0.001), 6.7 for depressive
episodes (χ2 = 24.7, P < 0.001), and 2.5 for manic or mixed episodes (χ2 = 9.0, P < 0.05).
Conclusion: This naturalistic follow-up study provides preliminary evidence for the efficacy of
long-term add-on quetiapine treatment in the prevention of relapses of manic or mixed and
depressive episodes of bipolar I disorder, and particularly in the prevention of depressive episodes.
Background
Bipolar I disorder is a severe and chronic illness character-
ized by episodes of mania and depression [1]. Two major
challenges of treating bipolar I disorder are the high per-
centage of patients who do not respond to therapy and the
high percentage of patients who relapse after initially
responding. To address these challenges, patients are
often given long-term treatment with combinations of
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drugs from different classes [2]. Quetiapine is an atypical
antipsychotic with a superior tolerability profile to con-
ventional antipsychotics. Large, placebo-controlled stud-
ies have shown the efficacy of quetiapine for treating both
acute manic episodes (as monotherapy and combination
therapy) and acute depressive episodes (as monotherapy)
associated with bipolar disorder [3-6].
Objective
To assess the long-term response to add-on quetiapine
therapy in patients with bipolar I disorder who were not
adequately responding to standard medications.
Methods
Study design
An open-label study of patients with bipolar I disorder
inadequately responsive to ongoing medications who
were prospectively observed for 3–18 months before
receiving add-on quetiapine treatment for 6–42 months.
Study population
Adult outpatients with bipolar I disorder (based on DSM-
IV-TR) [7] who had responded inadequately to prior
standard treatment. Inadequate response to prior treat-
ment was defined as a Clinical Global Impressions scale
for Bipolar Disorder (CGI-BP) [8] score ≥ 3 with no
improvement in score after 3 months of therapy. Patients
who were pregnant or breastfeeding, or had a recent his-
tory of alcohol or drug abuse, were excluded. Written con-
sent for the study was obtained after giving patients a
complete description of the study.
Study medication
Quetiapine was added to ongoing medication at an initial
dose of 25 mg/d for the first 2 days, increased to 50 mg/d
for the next 2 days, and then increased by 50 mg incre-
ments every 2 days until a clinical response was observed
(up to a maximum dose of 800 mg/d). This dose was then
maintained throughout the remainder of the study.
Assessments
Prospective evaluations were made at least once every 2
months and no fewer than 8 times per year. Clinical
response was evaluated using the CGI-BP scale [8]. The
relative risk of relapse, defined as the number of relapse
events per patient-year of treatment, was determined for
the period before initiating quetiapine. Relapse events
included hospitalization, treatment in a day hospital or
clinic, or an increase of ≥ 1 in CGI-BP [8] score accompa-
nied by a change in therapy.
Statistical methods
Mean CGI-BP scores were compared by one-way analysis
of variance (ANOVA) for repeated measures. Confidence
intervals for comparing the relative risks of relapse were
calculated using the simplified method of Miettinen [9].
Results
Patient and treatment characteristics
Of the 61 patients, 41% were male (mean age 41.4 ± 8.2
years) and 59% were female (mean age 47.2 ± 16.9 years).
Patients were prospectively observed for 3–18 months
(average 7.5 months) before quetiapine therapy was
added. Patients' ongoing medications are listed in Table 1.
Add-on quetiapine therapy was maintained for 6–42
months (average 15.7 months) until study termination.
Fourteen patients received quetiapine add-on therapy for
≥ 24 months. The final mean quetiapine dose was 537.1 ±
91.7 mg/day. Four patients discontinued the study: 1 due
to adverse effects (hypotension and drowsiness) and 3
due to non-adherence after the first evaluation at 6
months.
Efficacy
Risk of relapse
The overall relapse rate decreased following the addition
of quetiapine (Table 2, Figure 1). When analyzed by epi-
sode type, the relapse rates of depressive and manic/
mixed episodes also decreased after adding quetiapine
compared with the period before adding quetiapine
(Table 2, Figure 1). Relative risks of relapse for all epi-
sodes, manic episodes, and depressive episodes prior to
quetiapine treatment are shown in Table 2.
Symptom improvement
Mean change in CGI-BP score showed a significant
improvement in symptoms from baseline at 6, 12, 18, and
24 months (P < 0.001; Table 3).
Tolerability
Side effects during quetiapine combination therapy
(Table 4) were generally mild or moderate. Mild extrapy-
ramidal symptoms (EPS) were reported by 4 patients
(6.5%), all of whom were taking lithium or divalproex.
No tardive dyskinesia was reported.
Annual relapse rates before and after add-on quetiapine  treatment Figure 1
Annual relapse rates before and after add-on quetiapine 
treatment.
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Conclusion
In patients with bipolar I disorder who had shown inade-
quate responses to prior standard therapy, relapse rates
and symptoms were significantly improved with 6
months of add-on quetiapine therapy. These improve-
ments were maintained in 14 patients treated for 24
months. Add-on quetiapine therapy was well tolerated,
with no incidences of tardive dyskinesia reported follow-
ing addition of quetiapine and only 4 patients reporting
mild EPS. This naturalistic follow-up study demonstrates
the efficacy of quetiapine in the prevention of relapses of
manic and depressive episodes of bipolar I disorder in the
long term, and particularly in the prevention of depressive
episodes, which is consistent with our earlier findings [10]
and with other follow-up studies concerning bipolar
depression [11], bipolar depression and rapid cycling dis-
ease course [12], rapid cycling bipolar disorders [13].
These results warrant confirmation in large, randomized,
placebo-controlled studies.
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Table 4: Side effects during add-on quetiapine treatment
Adverse event Patients, n (%)
Weight gain (> 7% of baseline 
body weight)
21 (34.4%)
Sedation 15 (24.6)
Asthenia 7 (11.4)
Insomnia 7 (11.4)
Dry mouth 5 (8.2)
Transient drowsiness 4 (6.5)
Headache 4 (6.5)
Constipation 3 (4.9)
EPS 4 (6.5)
Table 2: Relapse rates and relative risks of relapse before and 
after the addition of quetiapine to ongoing therapy
Before add-on 
quetiapine
After add-on 
quetiapine
Observation period 
(in months)
Average 7.5 15.7
Range 3–18 6–42
Relapse rate 
(episodes/year)
Any episode 2.09 0.61
Manic/mixed 
episodes
1.15 0.46
Depressive episodes 0.94 0.14
Relative risk of 
relapse before add-
on quetiapine
Any episode 3.4 (χ2 = 24.8, 95% CI 2.1–5.5; P < 0.001)
Manic/mixed 
episodes
2.5 (χ2 = 9.0, 95% CI 1.4–4.5; P < 0.05)
Depressive episodes 6.7 (χ2 = 24.7, 95% CI 3.7–14.0; P < 0.001)
Table 1: Ongoing medications*
Medication Number of patients
Carbamazepine 8
Chlorpromazine 5
Oxcarbazepine 2
Gabapentin 3
Haloperidol 8
Lithium 25
Olanzapine 5
Risperidone 4
Sodium valproate 14
*Some patients were treated with more than 1 of the listed 
medications.
Table 3: Mean CGI-BP scores before and after addition of 
quetiapine
CGI-BP Score (Mean ± SD)
Observation 
period
N Baseline* During 
observation
F-
ratio
P-value†
3 months before 
quetiapine
61 4.5 ± 1.1 4.3 ± 1.4
6 months after 
quetiapine
61 4.5 ± 1.1 3.4 ± 1.1 30.5 <0.001
12 months after 
quetiapine
47 4.7 ± 1.0 3.3 ± 1.3 34.3 <0.001
18 months after 
quetiapine
24 4.8 ± 0.9 3.6 ± 1.0 19.1 <0.001
24 months after 
quetiapine
14 4.4 ± 0.9 3.0 ± 0.9 16.9 <0.001
*Represents the start of quetiapine treatment except for the observation period at 
3 months before the start of quetiapine treatment
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